SCHEMBL4837548

SCHEMBL4837548

COC(=O)C(c1ccc(OCCNC(=O)OCc2ccccc2)cc1)C(C)C

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.66
MAPT P10636 1/20 0.66
LMNA P02545 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ITGB3 P05106 4/20 0.47
ITGA2B P08514 4/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
ACHE P22303 1/20 0.47
HTT P42858 1/20 0.46
SLC1A3 P43003 1/20 0.45
SLC1A1 P43005 1/20 0.45
LTA4H P09960 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4841700 0.89 L3MBTL1 (0.69) L3MBTL1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL5689355 0.85 L3MBTL1 (0.67) L3MBTL1MAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL3811564 0.82 L3MBTL1 (0.80) L3MBTL1MAPTLMNASMN1; SMN2NPC1
SCHEMBL9272300 0.80 L3MBTL1 (0.81) L3MBTL1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL6595110 0.79 L3MBTL1 (0.76) L3MBTL1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL6331080 0.79 L3MBTL1 (0.71) L3MBTL1MAPTLMNASMN1; SMN2MEN1
SCHEMBL9205258 0.79 L3MBTL1 (0.75) L3MBTL1MAPTLMNASMN1; SMN2MEN1
SCHEMBL20500014 0.78 L3MBTL1 (0.74) L3MBTL1MAPTLMNASMN1; SMN2MEN1
SCHEMBL20299180 0.78 L3MBTL1 (0.79) L3MBTL1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL8475955 0.78 L3MBTL1 (0.73) L3MBTL1MAPTLMNASMN1; SMN2ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119465-A1 Novel Indoline Compounds GPR119, INSR, IRS1 L3MBTL1 1493/4885MAPT 763/4885LMNA 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.